STOCK TITAN

Seshadri Neervannan to sell TARS shares (NASDAQ: TARS) — March dispositions listed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Seshadri Neervannan reported proposed and completed sales of Common Stock of TARS. The filing lists restricted shares vesting on 03/16/2026 (1,093 shares), 03/17/2026 (1,087 shares) and 03/18/2026 (809 shares). The filing also reports open-market sales during the prior three months of 8,366, 3,125, 3,610 and 4,589 shares on 03/04/2026, 03/17/2026, 03/18/2026 and 03/19/2026, respectively, with aggregate proceeds shown per sale.

Positive

  • None.

Negative

  • None.

Insights

Insider reported serial dispositions and recent restricted‑stock vesting.

The filing records multiple open‑market sales totaling disclosed per‑trade share counts on specific March dates and shows restricted stock vesting events of 1,093, 1,087 and 809 shares. The vesting items are listed as Compensation and are separate from the sales rows.

Cash‑flow treatment and any selling plan (e.g., Rule 10b5‑1) are not shown in the excerpt; subsequent filings or footnotes would be needed to confirm whether sales were pre‑arranged or discretionary.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What sales did Seshadri Neervannan report in the Form 144 for TARS?

The filing lists open‑market sales of 8,366, 3,125, 3,610, and 4,589 shares on 03/04/2026, 03/17/2026, 03/18/2026, and 03/19/2026. Each sale shows the gross proceeds for that trade.

Did the Form 144 show any shares vesting for the insider?

Yes. The filing shows restricted stock vesting on 03/16/2026 (1,093 shares), 03/17/2026 (1,087 shares) and 03/18/2026 (809 shares) and labels these items as Compensation.

What total number of shares were sold in the past three months as disclosed?

The disclosed open‑market sales sum to 19,690 shares across four trades in March 2026, with aggregate proceeds shown for each trade in the filing excerpt.

Does the filing state whether sales were part of a pre‑arranged plan?

The provided excerpt does not state whether the sales were executed under a Rule 10b5‑1 or other pre‑arranged plan. The filing shows trade dates and proceeds but no trading‑plan language.

Who is the broker or custodian shown on the filing for these transactions?

The excerpt lists Fidelity Brokerage Services LLC at 900 Salem Street, Smithfield, RI as the brokerage/custodian associated with the Common shares in the filing.
Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

View TARS Stock Overview

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

2.84B
40.38M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
IRVINE